Ganglioneuroma presenting as an adrenal incidentaloma: a case report

Mine Adas1, Bora Koc2*, Gokhan Adas3, Filiz Ozulker4 and Tamer Aydin5

Abstract

Introduction: Ganglioneuromas are rare benign tumors arising from the neural crest tissue and are most commonly located in the posterior mediastinum and retroperitoneum; they are rarely found in the adrenal gland. This tumor is usually asymptomatic and in the majority of cases is detected incidentally. Although the characteristics of adrenal ganglioneuroma on computerized tomography and magnetic resonance imaging have been well described, the exact diagnosis is difficult. Histopathological examination is currently the mainstay of diagnosis. Ganglioneuromas have a very good prognosis with surgical removal. We report the case of a male patient with an incidentally identified adrenal ganglioneuroma with high standardized uptake values in a positron emission tomography scan.

Case presentation: An 18-year-old Turkish male patient with no previous comorbidities was admitted to our hospital with lower-quadrant pain. He had no significant past medical or surgical history. A physical examination did not reveal any signs and the results of routine laboratory tests were all within the normal ranges. Our patient underwent computed tomography of his abdomen, which showed a relatively homogenous left adrenal tumor measuring 5.2x4.3x7.1cm. On a positron emission tomography scan, the left adrenal gland disclosed a standardized uptake value of 4.1. Our patient underwent an exploratory laparotomy with left adrenalectomy without any related complications.

Conclusion: Ganglioneuroma may sometimes be similar to other adrenal malignancies. Careful evaluation with endocrine tests and imaging procedures is necessary to provide an accurate diagnosis. Definitive diagnosis can be made by histological examination. The prognosis is very good with surgical removal.

Keywords: Adrenal ganglioneuroma, Adrenal gland, Incidentaloma

Introduction

Ganglioneuroma (GN) is a rare benign tumor arising from the neural crest tissue and most commonly located in the posterior mediastinum and retroperitoneum. GNs are rarely found in the adrenal gland [1,2]. This tumor is usually asymptomatic and, in the majority of cases, detected incidentally. Now that imaging procedures such as ultrasonography and computerized tomography (CT) are used more frequently, this unexpected and exceptional incidentaloma lesion can be detected more easily [3,4]. The prevalence of adrenal incidentaloma is 0.2% in young patients, 3% in populations past their fifth decade, and as high as 7% in those past their seventh decade [5].

Although adrenal GNs are usually hormonally inactive, some of them secrete catecholamines. Symptoms like hypertension, diarrhea and virilization may develop as a result of mixed hormone secretion; in such case the diagnosis will be controversial. Tumors that originate from the ganglion cells include GN (benign), ganglioneuroblastoma (intermediate differentiation) and neuroblastoma (highly malignant lesion). The imaging characteristics of adrenal GN are variable and some are very similar to other adrenal tumors such as adrenocortical carcinoma (ACC) and pheochromocytoma, a fact that is crucial in the clinic [4,6]. Therefore, it is generally challenging to obtain a precise differential diagnosis of adrenal GN prior to surgery. A definitive diagnosis can be made by histological examination.

In this case report, we present the case of an 18-year-old male patient with an adrenal tumor. The tumor was
found incidentally and was diagnosed as an adrenal GN during an evaluation of his right lower-quadrant pain.

Case presentation
An 18-year-old Turkish male patient with no previous comorbidities was admitted to our hospital with right lower-quadrant pain. He had no significant past medical or surgical history. A physical examination revealed no signs and the results of routine laboratory tests were all found to be within the normal ranges. Because of his symptoms, an abdominal ultrasound was performed and showed a heterogeneous, well-defined mass measuring 5×7cm at his left adrenal gland. Our patient was referred to the endocrinology department where he underwent abdominal CT, which showed a relatively homogenous left adrenal tumor measuring 5.2×4.3×7.1cm with faint calcification and well-defined edges. Magnetic resonance imaging (MRI) showed a solid mass measuring 5×4×7cm arising from his left adrenal gland. The tumor was slightly hypointense on T1A-weighted MRI, whereas it was slightly hyperintense on T2A-weighted MRI. After an intravenous injection of gadolinium, the mass showed a progressive, heterogeneous and delayed enhancement.

An endocrine workup, including urine catecholamine and cortisol levels and a 1mg overnight dexamethasone suppression test, was normal. Because of the tumor size, we performed an 18F-2-fluoro-deoxy-D-glucose-positron emission tomography (PET) scan to diagnose the malignant lesion. His left adrenal gland showed a standardized uptake value (SUV) of 4.1 (Figure 1). With these findings, it was not possible to conclude whether the adrenal tumor was benign or malignant.

For this reason, exploratory laparotomy was performed to allow a definite diagnosis. A left adrenalectomy was performed, with no related complication. The surgical specimen was an elastic tumor with a slightly lobular

Figure 1 Positron emission tomography and computerized tomography scans of the patient with a left adrenal tumor. 18F-2-fluoro-deoxy-D-glucose-positron emission tomography scans show a standard uptake value of 4.1 for a left adrenal mass measuring 5.2×4.3×7.1cm. (arrow shows the mass on computed tomography).
edge, measuring 4.4×5.1×7.3cm (Figure 2). The cut surface of the tumor was light brown, covered by a thin capsule without any evidence of hemorrhage or necrosis. On microscopy, the section showed irregular proliferation of spindle-shaped cells and scattered mature ganglionic cells with dystrophic changes and focal lymphocytic infiltration. No evidence was found for the malignancy. An immunohistochemical examination showed positive staining of the ganglion and Schwann cells for S-100, vimentin and synaptophysin (Figure 3). The tumor was diagnosed as a left adrenal GN. Our patient experienced no complications during his postoperative course. No recurrence was detected during the one-year follow-up visits.

Discussion
GN is a rare, differentiated and benign tumor arising from primordial neural crest cells that form the sympathetic nervous system [7]. On histology, it is composed of mature Schwann cells and ganglion cells with fibrous stroma [1,8]. GN is a member of a group of neurogenic tumors group that includes ganglioblastoma and neuroblastoma. It differs from other neurogenic tumors in its benign potential [7]. These non-functional and non-symptomatic masses are usually detected incidentally and are referred to as incidentaloma. Because of the improvements in CT and ultrasonography procedures, the number of incidentalomas found has recently increased. The pathology of adrenal incidentalomas may vary from a simple benign cyst or lipoma to adrenal carcinoma. The differential diagnosis of an adrenal mass comprises a long list including adenoma, myelolipoma, cyst, lipoma, pheochromocytoma, adrenal cancer, metastatic cancer, hyperplasia and tuberculosis [1-8]. Functioning tumors and carcinomas are not generally discovered incidentally because their diagnosis is based on specific signs and symptoms. It should be noted that some functional tumors may present a subclinical form without any specific symptoms and some malignant tumors may look like benign lesions in radiological evaluations. The diagnosis of an adrenal tumor as a pheochromocytoma depends on the ability to determine its catecholamine content by biochemical or histochemical methods. Although extra-adrenal tumors have also been designated as pheochromocytomas by some authors, the preferred terminology for such neoplasms is ‘extra-adrenal paraganglioma’. Terms such as ‘composite pheochromocytomas’ and ‘compound tumor of the adrenal medulla’ have been used to describe tumors containing pheochromocytoma together with foci of neuroblastoma, ganglioneuroblastoma, GN or malignant peripheral nerve sheath tumor [9]. Literature shows that about 71% of composite pheochromocytoma or paraganglioma coexist with GN. Like ordinary pheochromocytomas and paragangliomas, most cases of composite pheochromocytomas or paragangliomas were functional, with increased levels of catecholamines or corticotropin-releasing hormone [10].

Although GN is generally considered to occur more frequently in young people, some recent studies have shown that it may also be seen between the ages 40 and 50 [4,11]. GN is most commonly found in the posterior mediastinum and retroperitoneum, and the involvement of the adrenal gland is relatively rare (21%) [12]. Adrenal GN is usually regarded as having silent hormonal functions and therefore can be asymptomatic. Occasionally, composite tumors with pheochromocytoma are seen and they, rarely, can secrete cortisol and androgen [13,14]. Additionally, Geoerger et al. reported that up to 30% of patients with GN had elevated plasma and urinary catecholamine levels but that patients were rarely found to have symptoms of catecholamine excess [1]. By contrast, Koch et al. reported the case of a patient with a GN that was positive for vasoactive intestinal peptide, which is the product of ganglion cells [15]. Patients with vasoactive intestinal peptide-positive tumors such as GN and neuroblastomas may not have any symptoms or signs of vasoactive intestinal peptide secretion [16]. GN can also produce and secrete other hormones, such as testosterone, indicating the pluripotency of its precursor cell. In our patient, his tumor was hormonally inactive and asymptomatic [17]. GN is a benign neoplasm that originates from neural crest cells of sympathetic ganglia or adrenal medulla. The macroscopic characteristics of adrenal GN are an encapsulated mass with a firm consistency and a solid, homogeneous, grayish-white cut surface. Histopathological
examination shows mature ganglion cells and Schwann cells among a fibrous stroma. Using microscopy they can be classified in two main groups: mature and maturing. The mature type is composed of mature Schwann cells, ganglion cells and perineurial cells, whereas the maturing type consists of cells with different maturation levels, ranging from mature cells to neuroblasts with a similar stroma. According to immunohistochemical analysis, GN are characterized by reactivity for S-100, vimentin, synaptophysin and neuronal markers [14]. In our patient, a final pathological examination confirmed the diagnosis.

Although the imaging characteristic of adrenal GN on CT and MRI have been well described, the precise diagnosis of adrenal GN using radiological evaluation prior to surgery is difficult. Qing et al. reported that the misdiagnosis rate of adrenal GN on CT and MRI before surgery is 64.7% [4]. Adrenal GN is described as a well-circumscribed tumor with lobular shape and low attenuation. In the literature, intratumoral calcification has been determined in 0% to 29% of the cases [4,6]. On MRI, adrenal GN shows homogeneously low or intermediate signal intensity in T1-weighted images and heterogeneous slightly high signal intensity on T2-weighted images [14]. For a tumor size larger than 5cm, heterogeneity and calcification may suggest malignancy [18]. In our patient, because the size and heterogeneity of the mass made us suspect malignancy, we preferred to perform a PET scan prior to the surgery.

PET scans can help complete the picture obtained by CT and MRI when making a differential diagnosis between adrenal GN and ACC or metastasis. One study reported that all cases of ACC had a SUV of 3.0 or higher, and that the sensitivity and specificity to distinguish ACC from adenoma were 100% and 98%, respectively [19,20]. In another review of four patients with adrenal GN, the SUVs were between 1.5 and 2.9 [11]. The SUV in our case was 4.1, which also suggested ACC. A PET scan is one of the most helpful modalities to differentiate malignancy and adenoma. However, in rare cases it may still mislead the physicians.

Even though a lesion size greater than 4.5cm seems to be a strong predictor of malignancy, this is not correctly confirmed by histologic evaluations. In our patient, although his tumor was larger than 6cm and the SUV level on PET was above than 3.0, pathology confirmed a benign tumor. Recent studies recommended that non-secretory adrenal incidentalomas larger than 6cm or with suspicious features of malignancy on imaging procedures should be treated by adrenalectomy [3-7]. There is no medical treatment for such tumors. GN, although benign, can grow aggressively. Patients treated surgically for a benign neurogenic tumor have an excellent prognosis. Papavramidis et al. reported that adrenal GN should be resected by adrenalectomy, whereas retroperitoneal GN can be resected without adrenalectomy [21]. The role of laparoscopic adrenalectomy in patients with large adrenal lesions or potential malignancy remains controversial. The reduced hospital stay and morbidity have resulted in laparoscopic adrenalectomy becoming the procedure of choice for the surgical removal of a vast majority of small sized (<6cm) adrenal lesions [1,3,7]. The prognosis for an adrenal GN following surgical
Conclusion
An adrenal GN is a rare, hormonally silent benign tumor. GN can sometimes resemble other adrenal malignancies. Careful evaluation by endocrine tests and imaging procedures is necessary for an accurate diagnosis. A definitive diagnosis can be made by histological examination. The prognosis is very good with surgical removal.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
ACC: adrenal cortical carcinoma; CT: computer tomography; GN: ganglioneuroma; MRI: magnetic resonance imaging; PET: positron emission tomography; SUG: standard uptake value.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
MA and BK took care of patient and wrote the initial draft. BK and GA operated on the patient. TA performed the pathologic evaluation of the specimen. BK, GA and FO edited the manuscript and performed the literature review. All authors read and approved the final manuscript.

Acknowledgement
We thank Prof. Servet Karahan and Imak Bircan for discussion and suggestions about the diagnosis.

Author details
1 Department of Endocrinology, Okmeydani Training and Research Hospital, 34200 Şişli, İstanbul, Turkey.
2 Department of Surgery, Okmeydani Training and Research Hospital, 34200 Şişli, İstanbul, Turkey.
3 Department of Surgery, Bakirköy Training and Research Hospital, 34700 Bakirköy, İstanbul, Turkey.
4 Department of Nuclear Medicine, Okmeydani Training and Research Hospital, 34200 Şişli, İstanbul, Turkey.
5 Department of Pathology, Okmeydani Training and Research Hospital, 34200 Şişli, İstanbul, Turkey.

Received: 17 November 2013 Accepted: 17 February 2014 Published: 29 April 2014

References
1. 803. Georgiev B, Hero B, Harms D, Gebe J, Scheidhauer K, Berthold F. Metabolic activity and clinical features of primary ganglioneuromas. Cancer 2001, 91:1905–1913.
2. 804. Erem C, Ucuncu O, Nuhoglu I, Cinel A, Cobanoglu U, Demirel A, Koc E, Kocak M, Guvendi GF. Adrenal ganglioneuroma: report of a new case. Endocrine 2009, 35:293–296.
3. 805. Yamauchi K, Hara I, Takeda M. Two cases of ganglioneuroma. Urology 2006, 67:622.e1-e4.
4. 806. Qiong Y, Xin X, Jian W, U G, Xin Hui W, Bing L, Hui Jing W, Ying Hao S. Adrenal ganglioneuromas: a 10-year experience in a Chinese population. Surgery 2010, 147:854–860.
5. 807. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wied HS. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003, 138(5):424–429.
6. 808. Maveje S, Materne R, Detrembleur N, de Leval L, Defechereux T, Meurisse M, Hamoir E. Adrenal ganglioneuroma. A neoplasia to exclude in patients with adrenal incidentaloma. Acta Chir Belg 2007, 107:670–674.
7. 809. Joshi VV. Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (modification of Shimada classification). Pediatr Dev Pathol 2000, 3:184–195.
8. 810. Ertzinger FM, Weiss SW. Ganglioneuroma. In Soft Tissue Tumors 3rd edition. St Louis: Mosby-Year Book; 1995:929–964.
9. 811. Lack EE. Tumors of the Adrenal Gland and Extra-adrenal Paraganglia. Washington, DC: Armed Forces Institute of Pathology; 1997.
10. 812. Shahani S, Nudelman RL, Nakin R, Vism HS, Samson SL. Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol 2010, 8:652.
11. 813. Rhonseaux G, Nolet S, Latour M, Bruschi S, Gaboury L, Lacroix A, Panzini B, Arjane P, Coda H, Bourdeau I. Clinical and biochemical features of seven adult adrenal ganglioneuromas. J Clin Endocrinol Metab 2010, 95:3118–3125.
12. 814. Jan M, Shubha BS, Sethi S, Banga V, Bagga D. Retroperitoneal ganglioneuroma: report of a case diagnosed by fine-needle aspiration cytology, with review of the literature. Diagn Cytopathol 1999, 21:194–200.
13. 815. Charfi S, Ayadi L, Elouze S, Ghorbel R, Khabir A, Gouiaa N, Bahri I, Fakihaff I, Makki S, Selam-Bouadwa: T. Composite pheochromocytoma associated with multiple endocrine neoplasia type 2B. Ann Pathol 2007, 27:225–228.
14. 816. Sasaki SI, Yasuda T, Kaneto H, Otsuki M, Tabuchi Y, Fujita Y, Kubo F, Tsuji M, Fujikawa K, Kazumi R, Kitamura T, Miyawaka T, Katakami N, Kawamori D, Matsuoka TA, Imagawa A, Shimomura I. Large adrenal ganglioneuroma. Intern Med 2012, 51:2365–2370.
15. 817. Koch CA, Brouwers FM, Rosenblatt K, Burman RD, Davis MM, Vortmeyer AO, Pacak K. Adrenal ganglioneuroma in a patient presenting with severe hypertension and diarrhea. Endocr Relat Cancer 2003, 10:99–107.
16. 818. Kogner P. Neuroendocrine tumours in neuroblasts and ganglioneuromas. Prog Brain Res 1995, 104:325–338.
17. 819. Mack E, Sarto GE, Crummy AB, Carlson IH, Curet LB, Wu J. Virilizing adrenal ganglioneuroma. JAMA 1978, 239:2273–2274.
18. 820. Fassnacht M, Kenn W, Allolio B. Adrenal tumours: how to establish malignancy? J Endocrinol Invest 2004, 27:387–395.
19. 821. Mackie GC, Shuklin BL, Ribiero RC, Worden PF, Gauger PG, Mody R; Connolly LP, Hunter G, Rodriguez-Galindo C, Walks JW, Hurez CA, Schellingen DE. Use of [18F]-fluoro-deoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006, 91:2665–2671.
20. 822. Kulkarni AV, Bilbao JM, Cusumano MD, Muller PJ. Malignant transformation of ganglioneuroma into spinal neuroblastoma in an adult. Case report. J Neurosurg 1998, 88:324–327.
21. 823. Papavramidis TS, Michalopoulos N, Georgiou K, Kessigou I, Valenti T, Georgiou R, Papavramidis ST. Retroperitoneal ganglioneuroma in an adult patient: a case report and literature review of the last decade. South Med J 2009, 102(10):1065–1067.

Cite this article as: Adas et al.: Ganglioneuroma presenting as an adrenal incidentaloma: a case report. Journal of Medical Case Reports 2014 8:131.